These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27338196)

  • 1. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
    Guglielmetti L; Le Dû D; Veziris N; Caumes E; Marigot-Outtandy D; Yazdanpanah Y; Robert J; Fréchet-Jachym M;
    Eur Respir J; 2016 Aug; 48(2):582-5. PubMed ID: 27338196
    [No Abstract]   [Full Text] [Related]  

  • 2. Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: How Much Better Are They?
    Bastard M; Guglielmetti L; Huerga H; Hayrapetyan A; Khachatryan N; Yegiazaryan L; Faqirzai J; Hovhannisyan L; Varaine F; Hewison C
    Am J Respir Crit Care Med; 2018 Nov; 198(9):1228-1231. PubMed ID: 29969054
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ; Gibbert J; Wirth D; Diel R
    Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract]   [Full Text] [Related]  

  • 4. Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.
    Decroo T; Aung KJM; Hossain MA; Gumusboga M; Ortuno-Gutierrez N; De Jong BC; Van Deun A
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34561288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
    Park S; Lee KM; Kim I; Mok J
    Int J Infect Dis; 2018 Nov; 76():88-90. PubMed ID: 30244076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant tuberculosis and bedaquiline.
    Salfinger M; Somoskövi A
    N Engl J Med; 2014 Dec; 371(25):2435-6. PubMed ID: 25517715
    [No Abstract]   [Full Text] [Related]  

  • 7. Multidrug-resistant tuberculosis and bedaquiline.
    Diacon AH; Lounis N; Dannemann B
    N Engl J Med; 2014 Dec; 371(25):2436. PubMed ID: 25517714
    [No Abstract]   [Full Text] [Related]  

  • 8. Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.
    Kwon YS; Jeon D; Kang H; Yim JJ; Shim TS
    Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 33093123
    [No Abstract]   [Full Text] [Related]  

  • 9. Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.
    Furin J; Diacon AH; Andries K
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):4-5. PubMed ID: 28157457
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis.
    Deng G; Fu L
    Lancet Infect Dis; 2024 Sep; 24(9):940-941. PubMed ID: 38768618
    [No Abstract]   [Full Text] [Related]  

  • 12. Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Pontali E; D'Ambrosio L; Centis R; Sotgiu G; Migliori GB
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331046
    [No Abstract]   [Full Text] [Related]  

  • 13. Bedaquiline in multidrug-resistant pulmonary tuberculosis GENESIS-SEFH drug evaluation report.
    Borrego Izquierdo Y; López Briz E; Márquez Saavedra E
    Farm Hosp; 2015 Jan; 39(1):1-5. PubMed ID: 25680429
    [No Abstract]   [Full Text] [Related]  

  • 14. Bedaquiline for the treatment of drug-resistant tuberculosis.
    Bélard S; Heuvelings CC; Janssen S; Grobusch MP
    Expert Rev Anti Infect Ther; 2015 May; 13(5):535-53. PubMed ID: 25797824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.
    Cox E; Laessig K
    N Engl J Med; 2014 Aug; 371(8):689-91. PubMed ID: 25140952
    [No Abstract]   [Full Text] [Related]  

  • 16. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
    Tiberi S; De Lorenzo S; Centis R; Viggiani P; D'Ambrosio L; Migliori GB
    Eur Respir J; 2014 Jan; 43(1):289-92. PubMed ID: 23988772
    [No Abstract]   [Full Text] [Related]  

  • 17. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
    Nagabushan H; Roopadevi HS
    J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
    [No Abstract]   [Full Text] [Related]  

  • 19. Bedaquiline: Introducing a new drug to the MDR TB armamentarium.
    Kambili C
    Indian J Tuberc; 2016 Jul; 63(3):137-138. PubMed ID: 27865232
    [No Abstract]   [Full Text] [Related]  

  • 20. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India.
    Udwadia ZF; Amale RA; Mullerpattan JB
    Int J Tuberc Lung Dis; 2014 Nov; 18(11):1315-8. PubMed ID: 25299863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.